We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global Hemostasis/Coagulation Analyzers Market to Reach USD 9.5 Billion by 2026

By LabMedica International staff writers
Posted on 01 Oct 2018
The global hemostasis/coagulation analyzers market was valued at USD 3.65 billion in 2017 and is expected to grow at a CAGR of 9.9% over the period 2018 to 2026 to reach USD 9.55 billion by 2026, driven mainly by the growing incidence of blood disorders. More...
Technological innovations and miniaturization has led to the commercialization of several novel devices that have quick turnaround time and can also be used in point of care (POC) settings. Additionally, growing awareness and demand for technologically advanced medical treatments, government support and increasing adoption of laboratory automation are driving the demand for novel coagulation analyzers.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Based on test types, the routine coagulation tests segment holds the largest share of the global hemostasis/coagulation analyzers market, due to a large number of these tests being performed for almost all surgical procedures and treatments. However, the diagnostic hemostasis assays segment is expected to register a faster growth rate due to the increasing adoption of specific tests such as VWF assays and thrombophilia testing, led by the growing awareness and prevalence of coagulation disorders. Based on product types, the devices (analyzers) segment holds a larger revenue share of the global hemostasis/coagulation analyzers market, driven by higher cost and continuously increasing purchase of these systems in the laboratory as well as POC settings. Based on end users, the diagnostic laboratories segment dominates the global hemostasis/coagulation analyzers market, led by greater preference for analyzing samples in specialized laboratories. Hemostasis analyzers have a high uptake in research institutions on account of the surge in the number of clinical trials being undertaken to commercialize novel drugs for the treatment of coagulation disorders.

Geographically, North America dominates the global hemostasis/coagulation analyzers market in terms of revenue, due to the presence of developed healthcare infrastructure, various R&D initiatives, and a high number of organ transplant and general surgeries performed in the region. However, the hemostasis/coagulation analyzers market in Asia Pacific is expected to witness the fastest growth, driven by growing awareness about hemostasis, increasing prevalence of diseases, both genetic and lifestyle linked, and rising healthcare expenditure due to the rapid evolution of healthcare infrastructure in the untapped markets of the region.

The hemostasis industry is characterized by the presence of several multinational players who have intensified their R&D efforts for the development of technologically advanced and more accurate analyzers. The major players are also undertaking penetration measures to enter the untapped markets in the Asia Pacific and Middle East & Africa.

Related Links:
Research and Markets


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.